The Drug Salicylamide Is an Antagonist of the Aryl Hydrocarbon Receptor That Inhibits Signal Transduction Induced by 2,3,7,8-Tetrachlorodibenzo-P-Dioxin

Total Page:16

File Type:pdf, Size:1020Kb

The Drug Salicylamide Is an Antagonist of the Aryl Hydrocarbon Receptor That Inhibits Signal Transduction Induced by 2,3,7,8-Tetrachlorodibenzo-P-Dioxin [CANCER RESEARCH 64, 429–434, January 1, 2004] The Drug Salicylamide Is an Antagonist of the Aryl Hydrocarbon Receptor That Inhibits Signal Transduction Induced by 2,3,7,8-Tetrachlorodibenzo-p-dioxin Christopher J. MacDonald, Henry P. Ciolino, and Grace Chao Yeh Cellular Defense and Carcinogenesis Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute-Frederick, NIH, Frederick, Maryland ABSTRACT (a)pyrene, and heterocyclic amines such as 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine. These classes of xenobiotics are all 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a widespread environ- suspected human carcinogens. For example, TCDD, a widespread mental contaminant, that has been linked with a variety of deleterious environmental contaminant generated by a variety of industrial pro- effects on human health, including increased cancer rates and reproduc- tive anomalies. The detrimental effects of TCDD are mediated via the aryl cesses, has been linked to an increase in many types of human hydrocarbon receptor (AhR), a transcription factor that regulates the cancers, including hepatocellular cancer (3, 4). In animal models, expression of the carcinogen-activating enzymes cytochromes P-450 TCDD has been shown to cause acute toxicity (5), increased oxidative (CYP) 1A1, 1A2, and 1B1. In the present study, we examined the ability stress (6), impaired ovulation (7), and immunotoxicity (8). These of synthetic derivatives of salicylic acid to affect TCDD-stimulated AhR- effects in animal models are believed to closely reflect the deleterious mediated signal transduction in human hepatoma HepG2 cells. Salicyl- effects of TCDD in humans (9). TCDD has the highest affinity for the amide (SAL), an analgesic drug, caused a potent and long-lasting inhibi- AhR of any known compound, and is considered the prototypical AhR tion of TCDD-induced CYP enzyme activity. Acetylsalicylic acid (aspirin) ligand. Its interaction with the AhR is essential to its toxicity, as and the naturally occurring phytochemical salicylic acid had no effect on demonstrated in AhR-knockout mice, which are impervious to TCDD CYP activity. SAL inhibited the increase in CYP1A1, -1A2, and -1B1 exposure (10). mRNA levels that occurs on exposure to TCDD. TCDD-induced transcrip- tion of these genes was also inhibited by SAL, but not by aspirin or Because of the central role of the AhR in the toxicity of TCDD and salicylic acid, as demonstrated by luciferase reporter assays. The tran- genotoxicity of numerous xenobiotics, the development of inhibitors scription of the CYP1 family of genes is regulated by the interaction of of AhR-mediated signal transduction has been an important goal of TCDD-activated AhR with the xenobiotic-responsive element present in chemoprevention science. In the present study, we have examined the the promoter regions of these genes. As shown by electrophoretic mobility effects of the salicylates on the AhR and the metabolic pathway it shift assay, SAL completely blocked the binding of TCDD-activated AhR regulates. Salicylic acid was first identified in willow bark extracts as to the xenobiotic responsive element. Also, SAL substantially blocked the an active anti-inflammatory compound more than 200 years ago, and binding of TCDD to the cytosolic AhR. These results demonstrate that its synthetic derivative, acetylsalicylic acid (aspirin), has be used to SAL, a commonly used analgesic, is a potent inhibitor of AhR-mediated treat a number of human maladies for over a century. Recent studies signal transduction, and may be an effective agent in the prevention of have demonstrated that salicylate usage is associated with a reduction TCDD-associated disease. of incidence of several types of cancer (11–13), and animal studies have shown that salicylates are potent inhibitors of chemically in- INTRODUCTION duced carcinogenesis (14, 15). We have, therefore, examined the effects of salicylates on the AhR function in HepG2 cells, a well- The aryl hydrocarbon receptor (AhR) is a ubiquitously expressed differentiated human liver cancer cell line that has been extensively cytosolic protein that is a member of the basic helix–loop–helix used as a model system to study the AhR (16–19). We demonstrated Per-Arnt-Sim super family of transcriptional regulatory proteins (1, that the synthetic salicylate, salicylamide (SAL), is a potent and 2). On binding the ligand, the “activated” AhR translocates to the long-lasting inhibitor of TCDD-induced signal transduction mediated nucleus, in which it forms a heterodimer with its partner, the aryl by the AhR. hydrocarbon nuclear translocator. Together, they form a transcription factor that binds to the xenobiotic-responsive element (XRE) present in the promoter region of a number of genes. The best characterized MATERIALS AND METHODS molecular response to AhR activation is the transcriptional induction Materials. Human hepatoma HepG2 cells were from American Type Cul- of CYP1A1, CYP1A2, and CYP1B1, the genes that encode the 1A1, ture Collection (Manassas, VA). RPMI 1640, TRIzol, and LipofectAMINE 1A2, and 1B1 enzyme isoforms, respectively, of cytochrome P-450 were from Life Technologies, Inc. (Grand Island, NY). Glutamine and fetal (CYP). These enzymes catalyze the epoxidation of certain classes of bovine serum were from BioFluids (Rockville, MD). Polydeoxyinosinic-de- xenobiotics, resulting in the generation of highly reactive electrophilic oxycytidylic acid, protease inhibitors, ethoxyresorufin, acetylsalicylic acid metabolites. These metabolites can covalently bind specific residues (aspirin), salicylic acid and SAL were from Sigma (St. Louis, MO). [32P]dATP 32 of DNA, causing DNA adduct formation that may result in mutation and [ P]dCTP were from DuPont-NEN (Boston, MA). TCDD was from the 3 and subsequent cellular transformation. The AhR and the genes that it Midwest Research Institute (Kansas City, MO). [ H]TCDD was from Chem- syn Science Labs, Lanexa, KS. The Omniscript kit was from Qiagen (Valencia, regulates are, therefore, central in mediating the genotoxicity of many CA). Tris-borate gels, Tris-borate running buffer, and high-density sample environmental contaminants. buffer were from Invitrogen (Carlsbad, CA). Ligands of the AhR include several classes of environmental car- Cell Culture. HepG2 human hepatoma cells were grown with RPMI 1640 cinogens, including polyhalogenated biphenyls such as 2,3,7,8-tetra- supplemented with 2 mM glutamine and 10% fetal bovine serum in a 5% CO2 chlorodibenzo-p-dioxin (TCDD), aryl hydrocarbons such as benzo- humidified incubator at 37°C. For all of the treatment compounds, DMSO was used as the vehicle and did not exceed 0.1%. Received 4/10/03; revised 9/23/03; accepted 9/29/03. Carcinogen Activation Capacity in HepG2 Cells. The ability of SAL to The costs of publication of this article were defrayed in part by the payment of page affect CYP enzyme activity was evaluated in intact cells by measurement of charges. This article must therefore be hereby marked advertisement in accordance with ethoxyresorufin-O-deethylase (EROD) activity. In 24-well plates, HepG2 cells 18 U.S.C. Section 1734 solely to indicate this fact. were incubated with increasing concentrations of salicylates in the presence of Requests for reprints: Grace Chao Yeh, Basic Research Laboratory, Building 538/ Room 141, National Cancer Institute-Frederick, Frederick, MD 21702-1201. Phone: 1nM TCDD for 24 h, for dose-response experiments. For time course exper- (301) 846-5369; Fax: (301) 846-6395; Email: [email protected]. iments, cells were incubated with increasing concentrations of SAL, or with 429 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 2004 American Association for Cancer Research. SAL INHIBITS AhR FUNCTION AND CYP1 EXPRESSION Ligand-Binding Assay. AhR ligand binding was measured according to the methods of Raha et al. (26). Cytosolic protein (1.5 mg/500 ␮l) was incubated with 20 nM [3H]TCDD in the presence of DMSO (5 ␮l/500 ␮l), 5 mM SAL, or 10 ␮M TCDD (unlabeled) for2hat4°C. Samples were centri- fuged in linear gradients of 5–30% sucrose (v/v) in 12 ml of Beckman Quick-Seal rotor tubes at 65,000 rpm for2hat4°C in a Beckman VTI-65–1 rotor. Fractions (ϳ500 ␮l each) of the gradients were collected, and radioac- tivity was determined by scintillation counting. Statistical Analysis. Statistical analyses were performed with STATVIEW Statistical Analysis Software (SAS Institute, San Francisco, CA). Differences between group mean values were determined by a one-factor ANOVA, fol- lowed by Fisher’s protected least significant difference post hoc analysis for pairwise comparison of means. A two-sided P value of Ͻ0.05 was considered significant. CYP mRNA levels in Figs. 3 and 4 are shown on a linear scale. Fig. 1. Structures of salicylic acid, aspirin, and salicylamide (SAL). RESULTS other test compounds at concentrations that inhibit 50% (IC50), in the presence Effect of Salicylates on TCDD-Induced CYP Enzyme Activity. of1nM TCDD for various times from 6 to 144 h. Medium was decanted, and In this study, we examined three salicylates the structures of which cells were washed once with PBS. Medium containing 5 ␮M ethoxyresorufin are illustrated in Fig. 1. The cellular capacity for enzymatic acti- was added. Increasing fluorescence as a result of the conversion of vation of procarcinogens was measured by EROD assay. Treatment ethoxyresorufin to resorufin by CYP enzymes was measured using a CytoFluor of HepG2 cells with 1 nM TCDD resulted in an increase in multiwell plate reader (Applied Biosystems, Foster City, CA), with an exci- EROD-specific activity from nondetectable levels to 17 pmol/min/ tation of 530 nm and emission at 590 nm. The reaction was allowed to run for 30 min. well in controls (Fig. 2A). The addition of SAL caused a concen- Reverse Transcription-PCR. In 6-well plates, cells were treated with various concentrations of SAL alone, or with 100 pM TCDD, for 8 h. Cells were washed twice with PBS, and total RNA was isolated with TRIzol reagent per manufacturer’s instructions.
Recommended publications
  • Synthesis of Aspirin
    SYNTHESIS OF ASPIRIN I. OBJECTIVES AND BACKGROUND You will: synthesize acetylsalicylic acid (aspirin) by carrying out a simple organic reaction, separate your product from the reaction mixture by vacuum filtration, purify your product by recrystallization, perform a chemical test to identify the change in functional group from reactant to product, and determine the success of your synthesis by calculating the percentage yield of your product. INTRODUCTION Aspirin is one of the most widely used medications in the world. It is employed as an analgesic (pain relief), an anti-pyretic (fever control) and an anti-inflammatory. More recently, studies have indicated that daily intake of small doses of aspirin can lower the risk of heart attack and stroke in high-risk patients. The history of aspirin and its precursor dates back to ancient times. Documents attributed to Hippocrates, the father of modern medicine, from the 4th century B.C. refer to the alleviation of pain by chewing on the bark of a willow tree or ingesting a powder made from the bark and leaves of the willow. This remedy was passed on from generation to generation. Fast forward now to the 19th century, where the field of organic chemistry began to experience tremendous growth. By 1838, chemists had managed to isolate, purify and identify the component of willow bark that provided the analgesic benefit. The compound was named salicylic acid, which was based on the genus name of the willow. Efforts to market salicylic acid met with failure, due to an unfortunate side effect-- prolonged ingestion of salicylic acid led to stomach pain, and in some cases, ulcers.
    [Show full text]
  • Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep
    animals Article Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep Shashwati Mathurkar 1,*, Preet Singh 2 ID , Kavitha Kongara 2 and Paul Chambers 2 1 1B, He Awa Crescent, Waikanae 5036, New Zealand 2 School of Veterinary Sciences, College of Sciences, Massey University, Palmerston North 4474, New Zealand; [email protected] (P.S.); [email protected] (K.K.); [email protected] (P.C.) * Correspondence: [email protected]; Tel.: +64-221-678-035 Received: 13 June 2018; Accepted: 16 July 2018; Published: 18 July 2018 Simple Summary: Scarcity of non-steroidal anti-inflammatory drugs (NSAID) to minimise the pain in sheep instigated the current study. The aim of this study was to know the pharmacokinetic parameters of salicylic acid in New Zealand sheep after administration of multiple intravenous and oral doses of sodium salicylate (sodium salt of salicylic acid). Results of the study suggest that the half-life of the drug was shorter and clearance was faster after intravenous administration as compared to that of the oral administration. The minimum effective concentration required to produce analgesia in humans (16.8 µL) was achieved in sheep for about 0.17 h in the current study after intravenous administration of 100 and 200 mg/kg body weight of sodium salicylate. However, oral administration of these doses failed to achieve the minimum effective concentration as mentioned above. This study is of significance as it adds valuable information on pharmacokinetics and its variation due to breed, species, age, gender and environmental conditions.
    [Show full text]
  • Salsalate Tablets, USP 500 Mg and 750 Mg Rx Only
    SALSALATE RX- salsalate tablet, film coated ANDAPharm LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- Salsalate Tablets, USP 500 mg and 750 mg Rx Only Cardiovascular Risk NSAIDs may cause an increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (See WARNINGS and CLINICAL TRIALS). Salsalate tablets, USP is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery (See WARNINGS). Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (See WARNINGS). DESCRIPTION Salsalate, is a nonsteroidal anti-inflammatory agent for oral administration. Chemically, salsalate (salicylsalicylic acid or 2-hydroxybenzoic acid, 2-carboxyphenyl ester) is a dimer of salicylic acid; its structural formula is shown below. Chemical Structure: Inactive Ingredients: Colloidal Silicon Dioxide, D&C Yellow #10 Aluminum Lake, Hypromellose, Microcrystalline Cellulose, Sodium Starch Glycolate, Stearic Acid, Talc, Titanium Dioxide, Triacetin. CLINICAL PHARMACOLOGY Salsalate is insoluble in acid gastric fluids (<0.1 mg/mL at pH 1.0), but readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid.
    [Show full text]
  • Dentistry and Basic Non- Opioid Prescribing in Pain Dmitry M
    Dentistry and Basic Non- Opioid Prescribing in Pain Dmitry M. Arbuck, MD President, Indiana Polyclinic Clinical Associate Professor of Psychiatry and Pain Management, Marian University College of Osteopathic Medicine Clinical Assistant Professor of Psychiatry and Medicine, IU School of Medicine www.IndianaPolyclinic.com Version May 2020 1 Disclosures No disclosures currently (May 7, 2020) 2 Disclaimer ISDH Oral Health Program Disclaimer for courses or presentations: The information provided in this course or presentation does not, and is not intended to, constitute dental, medical, or legal advice; instead, all information, content, and materials available in this course or presentation are for general informational purposes only. You should contact an outside dentist, physician, or attorney to obtain dental, medical, or legal advice and prior to acting, or refraining from acting, on the basis of information contained in this course or presentation. All liability with respect to actions taken or not taken based on the contents of this course or presentation are hereby expressly disclaimed. 3 Goals of Pain Management • Decrease pain • Increase function • Utilize medications that limit unacceptable side effects, including addiction 4 Goals of This Presentation • Gain knowledge of appropriate use of NSAIDs and acetaminophen for pain management in dentistry • Improve insight into benefits and adverse effects of various NSAIDs • Learn appropriate alternatives to opioid use for pain management 5 Opioids: Use with Caution • Use of opioids for
    [Show full text]
  • SOME NEW DRUGS in the TREATMENT of RHEUMATIC FEVER by M
    Postgrad Med J: first published as 10.1136/pgmj.28.317.179 on 1 March 1952. Downloaded from I79 SOME NEW DRUGS IN THE TREATMENT OF RHEUMATIC FEVER By M. J. H. SMITH, M.PHARM., PH.D., F.R.I.C. Department of Chemical Pathology, King's College Hospital Medical School, London Introduction every 4 to 8 hours. Symptoms such as dizziness, The usefulness of salicylates in rheumatic fever drowsiness and nausea developed in a small pro- is unquestioned, though their undesirable side- portion of the subjects, but in no instance were effects on the gastro-intestinal tract and on the these side-effects serious. The substance differed special senses are a drawback in prolonged therapy. from salicylic acid in producing a depression of Attempts to find allied substances with a greater the central nervous system in laboratory animals safety margin have been made and three com- and a decrease in the prothrombin time in man. pounds, salicylamide, sodium gentisate and The favourable clinical reports have led to the y-resorcylic acid, have recently been introduced. proposal that a large well-controlled trial should The treatment of rheumatic fever with ACTH be made.6 and cortisone has been the subject of a number of general reviews1' 2 and will not be discussed in the Gentisic Acid (2: 5-dihydroxybenzoic acid) present article. The cost and scarcity of these COOH by copyright. materials have stimulated a search for simpler compounds with a similar physiological action and a cinchoninic acid derivative (HPC) for which an ACTH-like activity is claimed, has been tried \AOH clinically in acute rheumatic fever.
    [Show full text]
  • Salicylate, Diflunisal and Their Metabolites Inhibit CBP/P300 and Exhibit Anticancer Activity
    RESEARCH ARTICLE Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity Kotaro Shirakawa1,2,3,4, Lan Wang5,6, Na Man5,6, Jasna Maksimoska7,8, Alexander W Sorum9, Hyung W Lim1,2, Intelly S Lee1,2, Tadahiro Shimazu1,2, John C Newman1,2, Sebastian Schro¨ der1,2, Melanie Ott1,2, Ronen Marmorstein7,8, Jordan Meier9, Stephen Nimer5,6, Eric Verdin1,2* 1Gladstone Institutes, University of California, San Francisco, United States; 2Department of Medicine, University of California, San Francisco, United States; 3Department of Hematology and Oncology, Kyoto University, Kyoto, Japan; 4Graduate School of Medicine, Kyoto University, Kyoto, Japan; 5University of Miami, Gables, United States; 6Sylvester Comprehensive Cancer Center, Miami, United States; 7Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States; 8Department of Biochemistry and Biophysics, Abramson Family Cancer Research Institute, Philadelphia, United States; 9Chemical Biology Laboratory, National Cancer Institute, Frederick, United States Abstract Salicylate and acetylsalicylic acid are potent and widely used anti-inflammatory drugs. They are thought to exert their therapeutic effects through multiple mechanisms, including the inhibition of cyclo-oxygenases, modulation of NF-kB activity, and direct activation of AMPK. However, the full spectrum of their activities is incompletely understood. Here we show that salicylate specifically inhibits CBP and p300 lysine acetyltransferase activity in vitro by direct *For correspondence: everdin@ competition with acetyl-Coenzyme A at the catalytic site. We used a chemical structure-similarity gladstone.ucsf.edu search to identify another anti-inflammatory drug, diflunisal, that inhibits p300 more potently than salicylate. At concentrations attainable in human plasma after oral administration, both salicylate Competing interests: The and diflunisal blocked the acetylation of lysine residues on histone and non-histone proteins in cells.
    [Show full text]
  • Betamethasone and Salicylic Acid
    PATIENT & CAREGIVER EDUCATION Betamethasone and Salicylic Acid This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: Canada Diprosalic; RATIO-Topisalic What is this drug used for? It is used to treat skin irritation. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Fungal, TB (tuberculosis), or viral infection of the skin. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. Betamethasone and Salicylic Acid 1/6 What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists. Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you. Do not use longer than you have been told by the doctor.
    [Show full text]
  • 2 Pharmacology 3 Toxicity and Drug Safety 4 Clinical Applications Of
    1 General Aspects 1.1 History 1.2 Chemistry 2 Pharmacology 2.1 Pharmacokinetics 2.2 Cellular Modes of Action 2.3 Actions on Organs and Tissues 3 Toxicity and Drug Safety 3.1 Systemic Side Effects 3.2 Organ Toxicity 3.3 Non-Dose-Related (Pseudo)allergic Actions of Aspirin 4 Clinical Applications of Aspirin 4.1 Thromboembolic Diseases 4.2 Pain, Fever, and Inflammatory Diseases 4.3 Further Clinical Indications 1 General Aspects 1.1 History 1.1.1 Willow Bark and Leaves as Antipyretic, Anti-Inflammatory Analgesics 1.1.2 Salicylates as the Active Ingredient of Willow Bark and Other Natural Sources 1.1.3 Synthesis of Acetylsalicylic Acid and First Clinical Studies 1.1.4 Mode of Aspirin Action 1.1.5 Anti-Inflammatory/Analgesic Actions of Aspirin 1.1.6 Aspirin in the Cardiovascular System 1.1.7 Current Research Topics 1.2 Chemistry 1.2.1 Structures and Chemical Properties of Salicylates 1.2.2 Determination of Salicylates Acetylsalicylic Acid. Karsten Schrör Copyright Ó 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim ISBN: 978-3-527-32109-4 j5 1 General Aspects 1.1 The first known communication on the medi- History cal use of willow bark extracts in modern times came from Reverend Edward Stone from Chip- 1.1.1 ping Norton (Oxfordshire, England). In 1763, he Willow Bark and Leaves as Antipyretic, Anti- treated some 50 cases of aigues, fever, and inter- Inflammatory Analgesics mitting disorders with a powdered dry bark preparation of willow tree [3]. The doses were Medical Effects of Willow Bark Treatment of dis- about 20 gr(ains) [1.3 g] to a dram of water every eases by plants or extracts thereof is as old as the 4 h.
    [Show full text]
  • Opinion on Salicylic Acid (CAS 69-72-7) - Submission I - Corrigendum of 20-21 June 2019
    SCCS/1601/18 Final Opinion Corrigendum of 20-21 June 2019 Scientific Committee on Consumer Safety SCCS OPINION ON salicylic acid (CAS 69-72-7) Submission I The SCCS adopted the final Opinion by written procedure on 21 December 2018 Corrigendum of 20-21 June 2019 SCCS/1601/18 Final Opinion Opinion on salicylic acid (CAS 69-72-7) - Submission I - Corrigendum of 20-21 June 2019 ___________________________________________________________________________________________ ACKNOWLEDGMENTS Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are: For the preliminary and the final Opinion The SCCS members: Dr U. Bernauer Dr L. Bodin Prof. Q. Chaudhry (SCCS Chair) Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG) Prof. M. Dusinska Dr J. Ezendam Dr E. Gaffet Prof. C. L. Galli Dr B. Granum Prof. E. Panteri (Rapporteur) Prof. V. Rogiers (SCCS Vice-Chair) Dr Ch. Rousselle Dr M. Stepnik Prof. T. Vanhaecke Dr S. Wijnhoven External experts: Dr A. Simonnard Dr A. Koutsodimou Prof. W. Uter The additional contribution of the following external expert is gratefully acknowledged: Dr. N. von Goetz All Declarations of Working Group members are available on the following webpage: http://ec.europa.eu/health/scientific_committees/experts/declarations/sccs_en.htm This Opinion has been subject to a commenting period of a minimum eight weeks after its initial publication (from 10 September until 14 November 2018). Comments received during this time were considered by the SCCS. For this Opinion, comments received resulted in the following main changes: sections 3.3.1.1.
    [Show full text]
  • University of Groningen Reflections on Flurbiprofen Eyedrops Van Sorge
    University of Groningen Reflections on flurbiprofen eyedrops van Sorge, Adriaan Alastair IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2002 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): van Sorge, A. A. (2002). Reflections on flurbiprofen eyedrops. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 REFLECTIONS ON FLURBIPROFEN EYEDROPS REFLECTIONS ON FLURBIPROFEN EYEDROPS RIJKSUNIVERSITEIT GRONINGEN REFLECTIONS ON FLURBIPROFEN EYEDROPS REFLECTIONS ON FLURBIPROFEN EYEDROPS PROEFSCHRIFT ter verkrijging van het doctoraat in de Wiskunde en Natuurwetenschappen aan de Rijksuniversiteit Groningen, op gezag van de Rector Magnificus, dr. F. Zwarts, in het openbaar te verdedigen op maandag 2 december 2002 om 14.15 uur door Adriaan Alastair van Sorge geboren op 28 oktober 1944 te New Rochelle, New York, USA PROMOTORES Prof.
    [Show full text]
  • HCHS/SOL Question by Question Instructions Medication Use Form (MUE/MUS), Version A
    HCHS/SOL Question by Question Instructions Medication Use Form (MUE/MUS), Version A General Instructions The purpose of the Medication Survey is to assess medication usage in the four weeks preceding the examination date. Information on both prescription and over-the-counter medications is ascertained via scanning of bar code symbols, transcription of labels, and interview. To obtain this information, the participant is asked prior to the clinic visit to bring to the field center all medications, over-the counter preparations, vitamins, minerals, and dietary supplements taken in the four-week period preceding the visit, or their containers. Notification of this request is mailed to the participant with the written instructions for the exam visit, and is re-stated during the appointment reminder call. Interviewers require certification in interviewing techniques and familiarity with the data entry procedures for electronic and paper versions of the form (references: Data Entry System [DES] manual and the “General Instructions for Completing Paper Forms”). Paper data entry and subsequent keying will only be used in the event of equipment malfunction or DES inaccessibility. Scanners / transcribers of medication information also require certification. Header information (ID Number, Contact Occasion, and Seq #) are completed in the format described in the cited document. Question by Question Instructions Part A. Reception Item 1 Read as written. If the response is “Yes, all”, go to Section B (MEDICATION RECORD) and begin the scanning/transcription. This can take place at the reception station or while the participant proceeds with the clinic visit. As the participant delivers the medications, indicate where (and by whom) they will be returned before he / she leaves.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]